Matthew Sykes
Stock Analyst at Goldman Sachs
(4.03)
# 540
Out of 5,149 analysts
210
Total ratings
54.42%
Success rate
10.52%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $10.56 | -52.65% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.43 | -32.28% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $23.14 | -71.91% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $39.81 | +13.04% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $5.01 | +59.68% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $45.89 | +4.60% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $15.91 | +6.85% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $108.27 | +47.78% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $9.50 | +5.26% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $95.59 | +30.77% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $8.81 | +58.91% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $206.00 | +16.50% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $18.75 | +38.70% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $178.61 | -4.82% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $92.23 | -39.28% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $74.20 | +7.82% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.62 | -7.41% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $200.17 | -5.08% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $2.32 | -24.57% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.61 | +17.73% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $36.01 | +2.75% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $103.35 | -37.11% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $174.27 | +43.46% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $6.33 | +279.15% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,325.09 | -1.89% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $7.05 | +70.21% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $508.58 | +25.84% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $118.17 | +22.70% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $48.83 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $10.56
Upside: -52.65%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.43
Upside: -32.28%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $23.14
Upside: -71.91%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $39.81
Upside: +13.04%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $5.01
Upside: +59.68%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $45.89
Upside: +4.60%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $15.91
Upside: +6.85%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $108.27
Upside: +47.78%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $9.50
Upside: +5.26%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $95.59
Upside: +30.77%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $8.81
Upside: +58.91%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $206.00
Upside: +16.50%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $18.75
Upside: +38.70%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $178.61
Upside: -4.82%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $92.23
Upside: -39.28%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $74.20
Upside: +7.82%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.62
Upside: -7.41%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $200.17
Upside: -5.08%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $2.32
Upside: -24.57%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.61
Upside: +17.73%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $36.01
Upside: +2.75%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $103.35
Upside: -37.11%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $174.27
Upside: +43.46%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $6.33
Upside: +279.15%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,325.09
Upside: -1.89%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $7.05
Upside: +70.21%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $508.58
Upside: +25.84%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $118.17
Upside: +22.70%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $48.83
Upside: -